A Comparative Analysis of the Efficacy of Blood Exchange Therapy in Neonatal Hyperbilirubinemia Induced by ABO and Rh Incompatibility
Kunhai Wu,Lufei Chen,Huifang Huang,Dengkai Chen
DOI: https://doi.org/10.2147/ijgm.s497184
IF: 2.145
2024-12-10
International Journal of General Medicine
Abstract:Kunhai Wu, 1, &ast Lufei Chen, 1 Huifang Huang, 2, &ast Dengkai Chen 1 1 Blood Transfusion Department, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, People's Republic of China; 2 Intensive Care Unit, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, People's Republic of China &astThese authors contributed equally to this work Correspondence: Huifang Huang, Email Background: This study challenges the prevailing view that hemolytic diseases of the newborn (HDN) associated with the Rh blood group system are more severe than those caused by the ABO system. The objective was to assess the effectiveness of exchange transfusion (ET) in managing HDN, with a focus on comparing treatment outcomes between ABO and Rh incompatibility cases. Methods: A study enrolled 125 neonates diagnosed with hyperbilirubinemia, comprising 66 males and 59 females. The gestational age of the neonates ranged from 33 to 41 weeks, and their birth weights varied between 2.11 to 4.3 kilograms. Based on the etiology of hemolysis, the study categorized 73 cases as ABO group and 52 as Rh group. Results: Post- ET, there was a significant reduction in serum total bilirubin (STB), serum indirect bilirubin (SIB), and platelet (PLT) counts (P< 0.001). Pre- ET, differences in SIB and PLT were noted between neonates with ABO and Rh incompatibilities (P< 0.05). There was no statistically significant disparities in the therapeutic effects of ET on STB, SIB, and PLT levels when comparing male and female neonates across both the ABO and Rh incompatibility groups. Conclusion: Our study demonstrated that ET is efficacious in reducing bilirubin levels and platelet counts in neonates presenting with ABO and Rh blood group incompatibilities. Notably, the effectiveness of ET was found to be independent of the neonates' gender, a finding that underscores the universal applicability of this treatment approach. Our study observation contradicts the prevalent belief that HDN associated with the Rh system is inherently more severe than that linked to the ABO system. This revelation underscores the imperative for the swift implementation of ET in managing cases of severe hyperbilirubinemia. Keywords: exchange transfusion, hyperbilirubinemia, ABO incompatibility, Rh Incompatibility, neonate Neonatal hyperbilirubinemia is a common condition that can lead to severe consequences if left untreated, including kernicterus and neurodevelopmental disorders. 1 ET is a therapeutic intervention employed to rapidly reduce bilirubin levels in neonates with severe hyperbilirubinemia. 2,3 The causes of neonatal hyperbilirubinemia are complex and varied, Hemolysis caused by ABO and Rh blood group incompatibilities being prominent contributors. 4 ABO incompatibility occurs when the mother has antibodies against the infant's blood type, leading to the destruction of red blood cells and subsequent hyperbilirubinemia. 5 Similarly, Rh incompatibility arises from maternal antibodies attacking the infant's Rh-positive red blood cells. 6 Both conditions need effective treatment to mitigate the risks associated with severe hyperbilirubinemia. Preventive measures and early intervention play a important role in both ABO hemolytic disease and Rh hemolytic disease. The significance of these approaches lies in their potential to reduce the severity of the conditions and to prevent complications such as kernicterus and hydrops fetalis. ABO incompatibility is more common due to the high prevalence of type O blood. Rh incompatibility is less common but can have more severe outcomes. Historically, ABO hemolytic disease has been considered less severe compared to Rh hemolytic disease. 7 However, comparative analyses between ABO and Rh groups and the stratification by gender are limited. 8,9 The objective of our research was to assess the effectiveness of exchange transfusion (ET) in lowering serum bilirubin levels and platelet counts among neonates suffering from hyperbilirubinemia due to ABO and Rh blood group incompatibilities. Our investigation sought to challenge the conventional wisdom that hemolytic diseases of varying etiologies, specifically ABO and Rh, might differ in their response to ET. We hypothesized that ET would exhibit similar efficacy across both groups, regardless of the underlying cause of hemolysis. Additionally, we were intrigued by the potential influence of gender on the treatment outcomes, co -Abstract Truncated-
medicine, general & internal